Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?

• click to rate

  Posted by Two Blokes Jul 23 - Filed in Stock - 12 views
  
  Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.